COMPANY PROFILE

TRIANA Biomedicines

Explore full profile

Rationally designs molecular glue for high-value disease targets

Waltham, United StatesFounded 2019Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2022

Revenue $10–50M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About TRIANA Biomedicines

Triana Biomedicines is a biotech startup that operates in the pharmaceutical industry, specifically in the field of molecular glue discovery. The company's primary focus is on the development of innovative cancer treatments through a process known as targeted protein degradation (TPD). This process involves identifying disease-causing proteins and developing molecular glues that can bind to these proteins, marking them for degradation by the body's natural cellular machinery, the ubiquitin-proteasome system (UPS). This approach has the potential to target proteins that were previously considered "undruggable," opening up new possibilities for disease treatment.

Read full description

Triana Biomedicines serves a broad market, including healthcare providers and patients suffering from diseases that are currently difficult to treat due to the lack of effective drugs. The company's business model is centered around the discovery and development of new molecular glues, which are then patented and sold to healthcare providers or pharmaceutical companies.

The company's revenue is generated through the sale of these patented molecular glues and potential partnerships with larger pharmaceutical companies for the development and commercialization of new drugs. Triana Biomedicines prides itself on its team of experienced professionals from various backgrounds, led by CEO Dr. Trojer, who joined the company in November 2021.

Source: Dealroom company data